PND29 EFFICIENCY PROFILE IN THE NEUROLOGICAL REFERRALS EFFECTUATE REFERENCE SPECIALISTS: USE CASE-MIX SYSTEM ADJUSTED CLINICAL GROUPS  by Sicras-Mainar, A et al.
239 patients on eight different insomnia medications were
included: alprazolam (30), amitriptyline (33), eszopiclone (30),
melatonin (30), quetiapine (30), temazepam (27), trazodone
(30) and zolpidem (29). The mean age (SD) of the patients was
49.3 years (SD = 11.8): 78.2% were female, 68.6% Caucasian,
23.0% Hispanic and 2.9% Black. The TSQM domains had
good internal consistency, with Cronbach’s alpha for all
domains exceeding 0.83. After adjusting for patient age, race,
gender, self-reported severity and Bonferroni correction for mul-
tiple comparisons, patients on products for secondary insomnia
expressed lower TSQM scores than patients on products for
primary insomnia. Some differences were also observed when
comparing TSQM scores for individual medication with the
mean score from all patients. For example, patients on amitrip-
tyline had a signiﬁcantly lower score on effectiveness (p = 0.044)
while patients on quetiapine had a signiﬁcantly lower score on
side effects (p = 0.0005). CONCLUSIONS: When selecting an
insomnia medication, clinicians should consider the patient’s
underlying condition as well as differences in patient satisfaction
with insomnia medications.
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UTILIZATION PATTERNS OF ANTIEPILEPTIC DRUGS:
AN ITALIAN PRESCRIPTION DATABASE ANALYSIS
Menditto E, De Portu S, Cammarota S, Citarella A, Riegler S,
Mantovani LG
University of Naples, Federico II, Naples, Italy
OBJECTIVES:To assess the AntiEpileptic Drugs (AED) usage and
the prevalence of AED users in Campania, a region of approxi-
mately 5.8million inhabitants in the south of Italy during the years
2005–2006. METHODS: We collected, from an electronic
research database, all prescriptions for AEDs reimbursed in the
years 2005–2006 in 8 local-health-authorities (70% of the overall
population) of Campania. We calculated the number of subjects
receiving more than a single AED prescription, to estimate the
annual prevalence of AED users. Therefore we excluded users of
morphine-like analgesic (ATC-code N02A). Annual prevalence of
AED use was assessed in the entire sample, stratiﬁed by drug type
and age group. RESULTS: We identiﬁed 107,959 subjects. The
estimated crude 1-year prevalence of AED use increased from
16.6/1000 (53.0 % female) in 2005 to 19.5/1000 (54.4% female)
in 2006. Prevalence increased with age for both genders. Preva-
lence of AED use increased from 5.9/1000 in 2005 to 8.7/1000 in
2006 for ‘new’ AEDs while was stable for ‘old’ AEDs (8.4/1000 in
2005, 8.2/1000 in 2006), excluding association between old-new
and switchers. Themost frequent regimens were all monotherapy:
phenobarbital, gabapentin, valproic acid, carbamazepina, lamot-
rigina were the most common AED in monotherapy in 2005,
pregabalin became ﬁrst in 2006when gabapentin went off-patent.
CONCLUSIONS: The results of the study indicate an increasing
prevalence of AED use with special reference to ‘newer’ com-
pounds. The increase is mainly due to pregabalin, marketed in the
end of 2004 with indications for epilepsy and neuropathic pain.
Excluding pregabalin and gabapentin, commonly used for the
treatment of neuropathic pain, older AEDs are the most frequent
regimens. Probably older AEDs remain the ﬁrst line treatment for
epileptic disorders. This claim is in accordance with a previous
study conducted in Italy from a General-Practitioners database
(Savica et al., European Journal of Neurology, 2007).
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TRENDS IN RESEARCH INTO CENTRAL NERVOUS SYSTEM
DISORDERS:THE INFLUENCE OF AN AGING POPULATION
Lock K, Samuels E
Heron Evidence Development Ltd, Letchworth Garden City, UK
OBJECTIVES: One of the consequences of an aging population
is the emerging importance of genetically-linked disorders which
develop in later life. Many of these disorders affect the central
nervous system and result in progressive degeneration of higher
functions and dementia. This research expands on observations
described in a previous presentation (PMC53, ISPOR 2008) con-
cerning the inﬂuence of genetic discoveries on the number of
probable RCTs in Alzheimer’s disease (AD) and Huntington’s
disease (HD) to explore other measures of interest. METHODS:
A citation search was conducted in Medline for the years 1951 to
2005 (5-yearly time periods). Search ﬁlters for RCTs, economic
studies (ES), and observational studies (OS) (www.sign.ac.uk/
methodology/ﬁlters.html) combined with search strings incorpo-
rating the MeSH terms for each disorder were run to provide an
estimate of interest in these disorders. The x-fold increases
(2001–2005/1976–1980) were calculated and the data were
analysed using logistic regression. RESULTS: There were
12,820,265 publications during 1951 to 2005, with 57,466 relat-
ing to AD and 8304 relating to HD. Over the past 30 years the
interest in AD has been increasing, with 62-fold increases in the
number of papers published within this disease area. In contrast,
during the same time period publications in HD showed only a
4-fold increase. This disparity is particularly notable for probable
RCTs, where there were 405-fold increases in AD but only 5-fold
increases in HD. Interestingly the interest in AD predates the
identiﬁcation of several genetic linkages that occurred in the late
1990’s. Conversely, the discovery of huntingtin in 1993 appears
to have had little effect on interest in HD. CONCLUSIONS:
Improvements and advances in sanitation, nutrition and immu-
nisation against infectious diseases have combined with other
factors to reduce mortality and prolong life expectancies. One of
the most important consequences of increased life expectancy is
the emergence of genetically linked disorders which develop in
later life. Discovery of genetic linkage does not appear to be a
strong predictor of research activity, in the case of AD and HD.
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SYSTEM ADJUSTED CLINICAL GROUPS
Sicras-Mainar A1, Navarro-Artieda R2,Velasco-Velasco S1,
Llopart-Lopez JR1, Rejas J3
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OBJECTIVES: To determine the general referral and neurologi-
cal rate per center and the adjusted efﬁciency indexes, through
the retrospective implementation of the Adjusted Clinical Groups
(ACG) in a primary care setting. METHODS: Design
multicenter-retrospective study. Attended patients by ﬁve
primary care teams (PCT) during the year 2006 were included.
The main measurements were general parameters, age, gender,
dependent (visits and episodes) and morbidity of each patient
relative to each ACG. The referral rate was deﬁned as the quo-
tient between the number of referrals and the visits made. Efﬁ-
ciency Index (EI) was established dividing the observed by the
expected referrals obtained by indirect standardization. Statisti-
cal signiﬁcance: p < 0.05. RESULTS: Studied patients 80775
(use: 72.4%), 4.8  3.5 episodes and 7.9  8.2 visits/patient/
year. Percentage of visits with a referral was 9.0% (conﬁance
interval [CI]: 8.8–9.2); age: 44.8  22.8 years (women: 54.6%),
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p < 0.001. The average of referrals was of 70.5 per 100 attended-
patients/year (p < 0.001). 2.5% referrals of the total were made
to the neurological, being patient of greater age, with predomi-
nance of women and displaying the head pain/migraine as main
consultation reason. Visits and episodes explain 43.2%-73.9%
respectively (p < 0.001), the explanatory power of the classiﬁca-
tion’s variability was of 46.3% (p = 0.001) and the referral
20.1%. EI per center were: 0.97 (CI: 0.77–1.18), 0.79 (CI: 0.57–
1.01), 0.88 (CI: 0.62–1.14), 1.29 (CI: 0.94–1.65) and 0.91 (CI:
0.58–1.25), p = 0.023 (family practice) and 0.90 (CI: 0.47–1.33),
0.78 (CI: 0.35–1.21), 0.93 (CI: 0.43–1.44), 1.21 (CI: 0.60–1.82)
and 0.97 (CI: 0.39–1.56), p = 0.031 (pediatrics); respectively.
CONCLUSIONS: Adjusted morbidity by ACG explains an
important part of the referrals variability. A low percentage was
derived to neurology.The study results must be interpreted cau-
tiously even after adjustment by age, gender and morbidity.
Should the results be conﬁrmed it would allow an improvement
in the measurement of referrals for clinical management in the
PCT.
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NATIONAL GUIDELINE FOR MULTIPLE SCLEROSIS
TREATMENT IN BRAZILIAN PUBLIC HEALTH:AN ANALYSIS
OFTREATMENT PATTERNS AND BUDGET IMPACT
Bueno RLP, Pereira MF
FEI, São Paulo, Brazil
OBJECTIVES: To determine the budget impact of treatment
patterns for Multiple Sclerosis (MS) based on national guideline.
METHODS: A one-year (October 2006 to September 2007)
retrospective database search was conducted to identify medica-
tion used, costs, patient adherence and provision. The source of
data was the Ministry of Health public available database, called
DATASUS. The study were conduct in four steps: 1) Determine
the medicines codes in the public list; 2) Establish the relation-
ships among drugs and patients usage, based on national guide-
lines; 3) Analyze adherence pattern in the most relevant center in
Brazil, based on medication consumption; and 4) Determine the
budget impact for MS treatment. RESULTS: Medication for MS
was responsible by 13% of high cost medication supplied by
Public Sector in Brazil. During the period of analysis the costs
and number of patients grew more than 100%, in average
60,000 medications per month were supplied and a total 8.294
patients were treated. Patients treated were distributed among
therapeutics alternative as follow: 60.28% to interferon-1a (two
brands), 19.99% to interferon-1b and 19.74 to glatiramer
acetate. Five states out of 27 were responsible by 80% of patients
treated. It was possible to detect the beginning of drug associa-
tion. We found that 26% of patients adhere to disease treatment.
Treatment costs was higher than USD 9 millions per month, the
distribution of costs is similar to the patients distribution due to
fewer combination therapy. CONCLUSIONS: National guide-
lines permits universal access, but the analysis of treatment pat-
terns points to a high concentration of care and this could be an
indicator of health care provision inequalities. Due to the high
costs of treatments and the fast patient growth rates new cost-
efﬁcient alternatives need to be considered as a way to reduce
health system inequalities.
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DESCRIPTIVE STUDY OFTHE PHARMACOLOGICAL
TREATMENTS USED IN PATIENTS WITH DEPRESSION IN
PARKINSON’S DISEASE (PD)
Sunderland TJ, Lee S, Das Gupta R
Boehringer Ingelheim, Bracknell, UK
Depression affects around 40–50% of people with PD [Goetz
2002]. It has been argued that depression in PD can be consid-
ered to be one of the manifestations of the degenerative nature of
the disease on the CNS [Shrag et al 2000]. Any differences in the
aetiology and co-morbidities in depression in PD when compared
to depression in those without PD may result in differences in
antidepressant treatment patterns. Furthermore, certain PD
drugs are metabolised in a way that may lead to their interaction
with certain antidepressants. Awareness of this may impact upon
prescribing decisions both for antidepressant and PD drugs in
those with depression in PD. OBJECTIVES: The objective of this
study is to describe the use of antidepressants in the treatment of
depression in PD patients. METHODS: The study was carried
out using the General Practice Research Database (GPRD). The
GPRD is a database with 9 million patients’ data (3.7 million
being currently active). The search identiﬁed PD patients on
various rates of different antidepressants. The PD patients were
diagnosed with PD from 2002 onwards. RESULTS: The study
identiﬁed 18,481 patients with a diagnosis of PD; 44% of these
also had a diagnosed depression (8,058 of 18,481). Of these PD
patients with depression, 21% had prescriptions for Amitrip-
tyline (1658 of 8058), 19% for Fluoxetine (1549 of 8058),
14% for Citalopram (1125 of 8058), 7% for Venlafaxine
(566 of 8,058) and 5% for Mirtazapine (369 of 8058).
CONCLUSIONS: This study conﬁrms the results of previous
studies that there is a high prevalence of depression in PD patients.
Within a UK context, the study also identiﬁes that a large propor-
tion of these patients receive antidepressant treatments.
SENSORY SYSTEMS DISORDERS—Clinical Outcomes
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RISK OF PSYCHIATRIC DISORDERS AND HEALTH CARE
EXPENDITURES AMONG PATIENTS WITH MODERATETO
SEVERE PSORIASIS
Han C1, Zhao N2,Waters H2, Schenkel B1
1Johnson and Johnson Pharmaceutical Services, LLC, Horsham, PA,
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OBJECTIVES: To evaluate the risk of psychiatric disorders and
associated health care expenditures among moderate to severe
psoriasis (PsO) patients using data from a US health care claims
database. METHODS: PsO patients and controls without PsO
were identiﬁed from the PharMetrics health care claims database
using the ICD-9 code of 696.x. Patients with moderate to severe
PsO (N = 7971) had been diagnosed with PsO in both years 2003
and 2004, and had been treated with systemic therapies including
cyclosporine, methotrexate, acitretin, biologics, or phototherapy.
Controls (N = 31884) were matched with PsO cases in a 4:1 ratio
by gender, age, region, and previous time-in-plan. Psychiatric
disorders and anti-psychiatric therapies in year 2004 were com-
pared between groups. RESULTS: PsO cases were equally distrib-
uted between males (50.6%) and females with mean age of 47.2
years. Almost half of the patients received anti-inﬂammatory
drugs, 33.3% received biologic therapies, and 36.7% had photo-
therapy. Compared with controls, patients with moderate to
severe PsO had a statistically signiﬁcantly higher prevalence
(p < 0.01) of anxiety (6.94% vs. 4.37%, OR = 1.63), depression
(9.17% vs. 5.32%, OR = 1.80), bipolar disorder (1.10% vs.
0.51%,OR = 2.16), and delirium (0.25%vs. 0.14%,OR = 1.74).
There was no difference between PsO patients and controls in the
prevalence of dementia or schizophrenia (p > 0.05). Compared
with controls, a greater proportion of PsO patients had been
treated with antidepressants (6.12% vs. 0.90%, OR = 7.18),
anxiolytics (5.03% vs. 0.75%, OR = 7.04), anti-psychotics
(5.90% vs. 0.89%, OR = 6.97) or anti-manics (4.89% vs.
0.74%, OR = 6.93). PsO patients had higher total health care
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